10-K Decoder · All companies

Taysha Gene Therapies, Inc.

TSHA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$9.77M$8.33M+17.3%
Operating income−$110M−$91.5M−20.8%
Net income−$109M−$89.3M−22.1%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026

$Q3 2026Year earlierChange
Revenue$0K$0K
Operating income−$41.9M−$34.0M−23.2%
Net income−$39.1M−$32.7M−19.6%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Taysha Gene Therapies's revenue in FY2025?
$9.77M in FY2025 (Fiscal year ended Dec 31, 2025), +17.3% vs $8.33M a year earlier, per its 10-K filed Mar 2026.
Was Taysha Gene Therapies profitable in FY2025?
No: net income was −$109M and operating income −$110M in FY2025.
What was Taysha Gene Therapies's revenue in Q3 2026?
$0K (n/a vs a year earlier), per its Form 10-Q filed Nov 12, 2026.